Cargando…

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy

BACKGROUND: Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Christiansen, Mille Guldager, Pappot, Helle, Jensen, Pernille Tine, Mirza, Mansoor Raza, Jarden, Mary, Piil, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354345/
https://www.ncbi.nlm.nih.gov/pubmed/37462855
http://dx.doi.org/10.1186/s41687-023-00611-w
_version_ 1785074907027079168
author Christiansen, Mille Guldager
Pappot, Helle
Jensen, Pernille Tine
Mirza, Mansoor Raza
Jarden, Mary
Piil, Karin
author_facet Christiansen, Mille Guldager
Pappot, Helle
Jensen, Pernille Tine
Mirza, Mansoor Raza
Jarden, Mary
Piil, Karin
author_sort Christiansen, Mille Guldager
collection PubMed
description BACKGROUND: Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symptoms. The objective of this study was to identify items in the National Cancer Institute’s measurement system Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) appropriate for use in a PRO tool for a population of women with endometrial or ovarian cancer undergoing treatment with taxanes (paclitaxel or docetaxel) in combination with carboplatin. METHODS: A two-phase, sequential multi-methods approach was applied. In phase one, a comprehensive literature search was done to map the toxicity of the applied chemotherapeutics and phase III clinical studies. Phase two, which comprised selecting the PRO-CTCAE items, included discussions with and feedback from a patient advisory board, an additional literature search, and focus group interviews with senior oncologists and specialized oncology nurses. A national expert panel facilitated both phases in terms of carefully select items from the PRO-CTCAE library. RESULTS: Phase one identified 18 symptoms and phase two, three additional ones, leading to the inclusion of 21 PRO-CTCAE symptoms in the final PRO tool. Since PRO-CTCAE also contains one to three sub-questions on the frequency, severity, and interference with daily activities of symptoms, there were 44 potential items. CONCLUSIONS: This study describes taking a multi-method approach to selecting items from the PRO-CTCAE library for use in a population of women with endometrial or ovarian cancer undergoing chemotherapy. By systematically combining diverse approaches, we carefully selected 21 clinically relevant symptoms covered by 44 items in the PRO-CTCAE library. Future studies should investigate the psychometric properties of this PRO tool for women with endometrial or ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-023-00611-w.
format Online
Article
Text
id pubmed-10354345
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-103543452023-07-20 A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy Christiansen, Mille Guldager Pappot, Helle Jensen, Pernille Tine Mirza, Mansoor Raza Jarden, Mary Piil, Karin J Patient Rep Outcomes Research BACKGROUND: Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symptoms. The objective of this study was to identify items in the National Cancer Institute’s measurement system Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) appropriate for use in a PRO tool for a population of women with endometrial or ovarian cancer undergoing treatment with taxanes (paclitaxel or docetaxel) in combination with carboplatin. METHODS: A two-phase, sequential multi-methods approach was applied. In phase one, a comprehensive literature search was done to map the toxicity of the applied chemotherapeutics and phase III clinical studies. Phase two, which comprised selecting the PRO-CTCAE items, included discussions with and feedback from a patient advisory board, an additional literature search, and focus group interviews with senior oncologists and specialized oncology nurses. A national expert panel facilitated both phases in terms of carefully select items from the PRO-CTCAE library. RESULTS: Phase one identified 18 symptoms and phase two, three additional ones, leading to the inclusion of 21 PRO-CTCAE symptoms in the final PRO tool. Since PRO-CTCAE also contains one to three sub-questions on the frequency, severity, and interference with daily activities of symptoms, there were 44 potential items. CONCLUSIONS: This study describes taking a multi-method approach to selecting items from the PRO-CTCAE library for use in a population of women with endometrial or ovarian cancer undergoing chemotherapy. By systematically combining diverse approaches, we carefully selected 21 clinically relevant symptoms covered by 44 items in the PRO-CTCAE library. Future studies should investigate the psychometric properties of this PRO tool for women with endometrial or ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-023-00611-w. Springer International Publishing 2023-07-18 /pmc/articles/PMC10354345/ /pubmed/37462855 http://dx.doi.org/10.1186/s41687-023-00611-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Christiansen, Mille Guldager
Pappot, Helle
Jensen, Pernille Tine
Mirza, Mansoor Raza
Jarden, Mary
Piil, Karin
A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title_full A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title_fullStr A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title_full_unstemmed A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title_short A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
title_sort multi-method approach to selecting pro-ctcae symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354345/
https://www.ncbi.nlm.nih.gov/pubmed/37462855
http://dx.doi.org/10.1186/s41687-023-00611-w
work_keys_str_mv AT christiansenmilleguldager amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT pappothelle amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT jensenpernilletine amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT mirzamansoorraza amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT jardenmary amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT piilkarin amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT christiansenmilleguldager multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT pappothelle multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT jensenpernilletine multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT mirzamansoorraza multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT jardenmary multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy
AT piilkarin multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy